Skip to main content
. Author manuscript; available in PMC: 2018 Jul 20.
Published in final edited form as: Best Pract Res Clin Haematol. 2017 Jun 15;30(3):222–228. doi: 10.1016/j.beha.2017.06.001

Fig. 2. Diagnostic algorithm for identifying children with Ph-like ALL in real-time.

Fig. 2

Patients with confirmed ABL class (blue) or JAK pathway (green) alterations are eligible to receive dasatinib (COG AALL1131) or ruxolitinib (COG AALL1521), respectively, in combination with chemotherapy post-induction.